论著

胆道恶性肿瘤晚期免疫检查点抑制剂相关性肺炎的临床评估和处理(附3例报告)

  • 孙学英 ,
  • 吴彬 ,
  • 蒋逸飞 ,
  • 廖卓君 ,
  • 赵金燕 ,
  • 周颖 ,
  • 张舒龙 ,
  • 王燕 ,
  • 刘厚宝
展开
  • 1.上海市徐汇区中心医院 复旦大学中山徐汇医院 a. 全科医学科;b. 普外科上海 200237
    2.复旦大学附属中山医院普外科复旦大学胆道疾病研究所,上海市胆道微创手术工程及材料研究中心上海 200032
王燕,E-mail: wang_yan1996@163.com
刘厚宝,E-mail: liuhbao@hotmail.com

收稿日期: 2025-05-30

  网络出版日期: 2026-01-26

基金资助

上海市徐汇区高原学科建设项目(SHXHZDXK202323);尖峰学科建设项目(SHXHZDXK202304);徐汇区公共卫生体系建设三年行动计划(2023-2025年)

Clinical evaluation and management of checkpoint inhibitor pneumonitis with advanced biliary tract cancer: a report of 3 cases

  • SUN Xueying ,
  • WU Bin ,
  • JIANG Yifei ,
  • LIAO Zhuojun ,
  • ZHAO Jinyan ,
  • ZHOU Ying ,
  • ZHANG Shulong ,
  • WANG Yan ,
  • LIU Houbao
Expand
  • 1a. Department of General Medicine, b. Department of General Surgery, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai 200237, China
    2. Department of General Surgery, Zhongshan Hospital, Fudan University; Biliary Tract Diseases Institute, Fudan University; Shanghai Engineering Research Center of Biliary Tract Minimal Invasive Surgery and Materials, Shanghai 200032, China

Received date: 2025-05-30

  Online published: 2026-01-26

摘要

目的:报道胆道恶性肿瘤晚期病人应用免疫检查点抑制剂致相关性肺炎(CIP)的病例,以期提供更多该疾病评估、治疗和监测的处理方法。方法:3例病人在化疗联合免疫治疗过程中,出现氧饱合度降低、肺间质病变。联合呼吸科诊断为CIP。急性期停止抗肿瘤治疗,并予糖皮质激素等治疗,定期监测病情变化。随访中,病例1肺转移;病例2好转;病例3合并感染且肿瘤进展。结果:糖皮质激素改善CIP病人的肺部病变及缺氧症状,但要关注合并其他感染及肿瘤进展的可能。结论:对于胆道晚期肿瘤病人,综合评估并早期识别CIP是非常重要的,尤其对应用糖皮质激素后病情反复的病人,要及时并精准调整治疗方案。

本文引用格式

孙学英 , 吴彬 , 蒋逸飞 , 廖卓君 , 赵金燕 , 周颖 , 张舒龙 , 王燕 , 刘厚宝 . 胆道恶性肿瘤晚期免疫检查点抑制剂相关性肺炎的临床评估和处理(附3例报告)[J]. 外科理论与实践, 2025 , 30(06) : 517 -523 . DOI: 10.16139/j.1007-9610.2025.06.10

Abstract

Objective To report cases of checkpoint inhibitor pneumonitis (CIP) in patients with advanced biliary tract cancer, aiming to provide additional approaches for the assessment, treatment, and monitoring of this condition. Methods Three patients developed oxygen desaturation and interstitial lung lesions during chemotherapy combined with immunotherapy, and were diagnosed with CIP in collaboration with the respiratory department. Antitumor therapy was discontinued in the acute phase, and glucocorticoids were administered, with regular monitoring of disease progression. During follow-up, case 1 developed lung metastasis; case 2 showed improvement; case 3 had concurrent infection and tumor progression. Results Glucocorticoids improved lung lesions and hypoxic symptoms in patients with CIP, but attention should be paid to the potential for concurrent infections and tumor progression. Conclusions Comprehensive assessment and early identification of CIP are crucial for patients with advanced biliary tract cancer. For those with recurrent symptoms after glucocorticoid therapy, timely and accurate adjustment of the treatment regimen is essential.

参考文献

[1] VOGEL A, BRIDGEWATER J, EDELINE J, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(2):127-140.
[2] CHEN S, HAN K, SONG Y, et al. Current status, trends, and predictions in the burden of gallbladder and biliary tract cancer in China from 1990 to 2019[J]. Chin Med J (Engl), 2022, 135(14):1697-1706.
[3] ZHOU J, TAN G, ZHANG L, et al. Epidemiology of biliary tract cancer in China: a narrative review[J]. Chin J Cancer Res, 2024, 36(5):474-488.
[4] 中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科专家工作组. 胆道恶性肿瘤转化治疗专家共识(2025)[J]. 中华外科杂志, 2025, 63(6):453-460.
  Branch of Biliary Surgery, Chinese Society of Surgery, Chinese Medical Association; Working Group of Biliary Surgeons, Chinese College of Surgeons, Chinese Medical Doctor Association. Expert consensus on conversion therapy of biliary tract cancer (2025)[J]. Chin J Surg, 2025, 63(6):453-460.
[5] OH D Y, HE A R, BOUATTOUR M, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study[J]. Lancet Gastroenterol Hepatol, 2024, 9(8):694-704.
[6] KELLEY R K, UENO M, YOO C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 401(10391):1853-1865.
[7] JIANG C, YANG L, KONG L Y, et al. Comparing immunotherapy versus chemotherapy alone as second-line therapy for malignant tumors of the biliary tract: a retrospective study[J]. Clin Med Insights Oncol, 2025, 19:11795549251317012.
[8] LAFACE C, FINA E, RICCI A D, et al. Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors[J]. Expert Opin Biol Ther, 2024, 24(12):1363-1374.
[9] PENG Z, DONG J, TANG S, et al. Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma[J]. Front Oncol, 2025, 15:1498887.
[10] FREY C, ETMINAN M. Adverse events of PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: an analysis of the FDA adverse events database[J]. Antibo-dies (Basel), 2024, 13(3):59.
[11] XU Y, CHEN R, PAN R, et al. Clinical management of checkpoint inhibitor pneumonitis: focus, challenges, and future directions[J]. Chin Med J Pulm Crit Care Med, 2025, 3(1):29-40.
[12] RASCHI E, ROSSI S, DE GIGLIO A, et al. Cardiovascular toxicity of immune checkpoint inhibitors: a guide for clinicians[J]. Drug Saf, 2023, 46(9):819-833.
[13] SIMBAQUEBA CLAVIJO C, ODARO O, GANDHI A, et al. Immunotherapy-related adverse events and clinical outcomes in adult solid-tumor patients admitted to an onco-hospitalist medicine service[J]. Cancers (Basel), 2025, 17(3):403.
[14] 中华医学会呼吸病学分会, 中国抗癌协会肿瘤呼吸病专业委员会, 北京肿瘤防治研究会. 免疫检查点抑制剂相关肺炎诊治和管理专家共识(2025)[J]. 中华结核和呼吸杂志, 2025, 48(4):329-343.
  Chinese Thoracic Society, Chinese Medical Association; Oncology Respiratory Disease Committee of China Anti-Cancer Association; Beijing Cancer Prevention and Treatment Research Association. Chinese experts consensus on the diagnosis and management of checkpoint inhibitor pneumonitis(2025)[J]. Chin J Tuberc Respir Dis, 2025, 48(4):329-343.
[15] LIN M X, ZANG D, LIU C G, et al. Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management[J]. Front Immunol, 2024, 15:1266850.
[16] WANG X, BAI Y, CHAI N, et al. Chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers[J]. Chin Med J (Engl), 2024, 137(19):2272-2293.
[17] CHEEMA P K, IAFOLLA M A J, ABDEL-QADIR H, et al. Managing select immune-related adverse events in patients treated with immune checkpoint inhibitors[J]. Curr Oncol, 2024, 31(10):6356-6383.
[18] HAANEN J, OBEID M, SPAIN L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(12):1217-1238.
[19] KARAYAMA M, INUI N, INOUE Y, et al. Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase Ⅱ study[J]. BMC Pulm Med, 2024, 24(1):495.
[20] SILVERSTEIN J, WRIGHT F, WANG M, et al. Evaluating survival after hospitalization due to immune-related adverse events from checkpoint inhibitors[J]. Oncologist, 2023, 28(10):e950-e959.
[21] VALENTE M, COLUCCI M, VEGNI V, et al. A multidisciplinary approach to improve the management of immune-checkpoint inhibitor-related pneumonitis[J]. Onco Targets Ther, 2024, 17:673-681.
[22] DAETWYLER E, WALLRABENSTEIN T, KONIG D, et al. Corticosteroid-resistant immune-related adverse events: a systematic review[J]. J Immunother Cancer, 2024, 12(1):e007409.
[23] VOGEL A, DUCREUX M, ESMO Guidelines Committee. ESMO clinical practice guideline interim update on the management of biliary tract cancer[J]. ESMO Open, 2025, 10(1):104003.
[24] ZHAO Y, YANG M, FENG J, et al. Advances in immunotherapy for biliary tract cancers[J]. Chin Med J (Engl), 2024, 137(5):524-532.
[25] THOMPSON J A, SCHNEIDER B J, BRAHMER J, et al. NCCN guidelines(R) insights: management of immunotherapy-related toxicities, version 2.2024[J]. J Natl Compr Canc Netw, 2024, 22(9):582-592.
[26] THOMPSON J A, SCHNEIDER B J, BRAHMER J, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(4):387-405.
[27] BADEN L R, SWAMINATHAN S, ALMYROUDIS N G, et al. Prevention and treatment of cancer-related infections, version 3.2024, NCCN Clinical Practice Guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(9):617-644.
文章导航

/